Vassilios Papademetriou

List of Publications by Year
in descending order

254	13,313	24978	24915
papers	citations	h-index	g-index

260	260	260	11435
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events. JAMA - Journal of the American Medical Association, 2001, 285, 1585.	3.8	843
2	Original Papers. Success and Predictors of Blood Pressure Control in Diverse North American Settings: The Antihypertensive and Lipidâ€Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Journal of Clinical Hypertension, 2002, 4, 393-404.	1.0	835
3	Prognostic Significance of Left Ventricular Mass Change During Treatment of Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2350.	3.8	740
4	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	6.3	597
5	Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol. Circulation, 2004, 110, 1456-1462.	1.6	435
6	Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril. JAMA - Journal of the American Medical Association, 2005, 293, 1595.	3.8	367
7	Effects of Intensive BP Control in CKD. Journal of the American Society of Nephrology: JASN, 2017, 28, 2812-2823.	3.0	364
8	Exercise Capacity and Mortality in Black and White Men. Circulation, 2008, 117, 614-622.	1.6	354
9	Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine. Headache, 2004, 44, 414-425.	1.8	327
10	Exercise Capacity and Mortality in Older Men. Circulation, 2010, 122, 790-797.	1.6	284
11	Effects of Regular Exercise on Blood Pressure and Left Ventricular Hypertrophy in African-American Men with Severe Hypertension. New England Journal of Medicine, 1995, 333, 1462-1467.	13.9	271
12	Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. European Heart Journal, 2013, 34, 2132-2140.	1.0	267
13	Impact of Different Partition Values on Prevalences of Left Ventricular Hypertrophy and Concentric Geometry in a Large Hypertensive Population. Hypertension, 2000, 35, 6-12.	1.3	216
14	Change in Diastolic Left Ventricular Filling After One Year of Antihypertensive Treatment. Circulation, 2002, 105, 1071-1076.	1.6	174
15	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International, 2015, 87, 649-659.	2.6	158
16	Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study)â^—â^—See Appendix for the list of LIFE investigators.. American Journal of Cardiology, 2000, 85, 466-472.	0.7	153
17	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertensionThe study on cognition and prognosis in the elderly (SCOPE). Journal of the American College of Cardiology, 2004, 44, 1175-1180.	1.2	152
18	Analysis of T-Wave Morphology From the 12-Lead Electrocardiogram for Prediction of Long-Term Prognosis in Male US Veterans. Circulation, 2002, 105, 1066-1070.	1.6	145

#	Article	IF	Citations
19	Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Journal of Hypertension, 2002, 20, 405-412.	0.3	139
20	Role of Diuretics in the Prevention of Heart Failure. Circulation, 2006, 113, 2201-2210.	1.6	137
21	Impact of Intensive Glycemic Control on the Incidence of Atrial Fibrillation and Associated Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus (from the Action to Control) Tj ETQq1 1 0.784314 rgBT /Overlock	3.4	137
22	Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control. Circulation, 2018, 137, 134-143.	1.6	134
23	Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. American Heart Journal, 2002, 143, 319-326.	1.2	130
24	Relation of Microalbuminuria to Adiponectin and Augmented C-Reactive Protein Levels in Men With Essential Hypertension. American Journal of Cardiology, 2005, 96, 946-951.	0.7	123
25	Exceptional early blood pressure control rates: The ACCOMPLISH trial. Blood Pressure, 2007, 16, 80-86.	0.7	114
26	Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension, 2001, 37, 19-27.	1.3	112
27	Diuretic-induced hypokalemia in uncomplicated systemic hypertension: Effect of plasma potassium correction on cardiac arrhythmias. American Journal of Cardiology, 1983, 52, 1017-1022.	0.7	110
28	Gender Differences in Hypertension: Myths and Reality. Current Hypertension Reports, 2013, 15, 321-330.	1.5	110
29	Echocardiographic Left Ventricular Geometry in Hypertensive Patients with Electrocardiographic Left Ventricular Hypertrophy: The LIFE Study. Blood Pressure, 2001, 10, 74-82.	0.7	105
30	Pathophysiology of Resistant Hypertension: The Role of Sympathetic Nervous System. International Journal of Hypertension, 2011, 2011, 1-7.	0.5	103
31	Effects of mental stress on coronary epicardial vasomotion and flow velocity in coronary artery disease: relationship with hemodynamic stress responses11The opinions and assertions expressed herein are those of the authors and should not be construed as reflecting those of the USUHS or the US Department of Defense.. Journal of the American College of Cardiology, 2001, 37, 1359-1366.	1.2	101
32	Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study.. Journal of Hypertension, 2001, 19, 1883-1891.	0.3	100
33	Exercise Capacity and Progression From Prehypertension to Hypertension. Hypertension, 2012, 60, 333-338.	1.3	98
34	Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension. Journal of the American College of Cardiology, 2004, 44, 1175-1180.	1.2	89
35	Blood Pressure Control Among US Veterans. Circulation, 2012, 125, 2462-2468.	1.6	88
36	Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. American Journal of Medicine, 1993, 94, 181-187.	0.6	84

#	Article	IF	Citations
37	EXERCISE AS HYPERTENSION THERAPY. Cardiology Clinics, 2001, 19, 507-516.	0.9	81
38	Low-dose drug combination therapy: An alternative first-line approach to hypertension treatment. American Heart Journal, 1995, 130, 359-366.	1.2	79
39	Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney Disease. Annals of Internal Medicine, 2017, 167, 375.	2.0	78
40	Change in Systolic Left Ventricular Performance After 3 Years of Antihypertensive Treatment. Circulation, 2002, 106, 227-232.	1.6	77
41	Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic) Tj ETQq1 1 0.784314 rgBT /Overlock	1.3	76
42	Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study. Journal of Hypertension, 2002, 20, 1445-1450.	0.3	75
43	The Study on COgnition and Prognosis in the Elderly (SCOPE) â€“ Major CV events and stroke in subgroups of patients. Blood Pressure, 2005, 14, 31-37.	0.7	75
44	Thiazide Therapy Is Not a Cause of Arrhythmia in Patients With Systemic Hypertension. Archives of Internal Medicine, 1988, 148, 1272.	4.3	73
45	Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension, 2012, 59, 926-933.	1.3	73
46	Pulse pressure/stroke index and left ventricular geometry and function. Journal of Hypertension, 2003, 21, 781-787.	0.3	71
47	Renal Sympathetic Denervation and Systemic Hypertension. American Journal of Cardiology, 2010, 105, 570-576.	0.7	70
48	Consequences of Adrenal Venous Sampling in Primary Hyperaldosteronism and Predictors of Unilateral Adrenal Disease. Journal of the American College of Surgeons, 2010, 211, 384-390.	0.2	70
49	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity. Journal of Hypertension, 2014, 32, 415-422.	0.3	70
50	Hypertension crisis. Blood Pressure, 2010, 19, 328-336.	0.7	69
51	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 2017, 40, 1401-1408.	4.3	68
52	Left ventricular wall stresses and wall stressâ€“massâ€“heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy. Journal of Hypertension, 2000, 18, 1129-1138.	0.3	66
53	Echocardiographic assessment by computer-assisted analysis of diastolic left ventricular function and hypertrophy in borderline or mild systemic hypertension. American Journal of Cardiology, 1985, 56, 546-550.	0.7	65
54	Catheter-Based Renal Denervation for Resistant Hypertension. Hypertension, 2014, 64, 565-572.	1.3	65

#	Article	IF	Citations
55	Air pollution and arterial hypertension. A new risk factor is in the air. Journal of the American Society of Hypertension, 2017, 11, 709-715.	2.3	65
56	Common Secondary Causes of Resistant Hypertension and Rational for Treatment. International Journal of Hypertension, 2011, 2011, 1-17.	0.5	64
57	Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). American Journal of Cardiology, 2002, 89, 337-341.	0.7	63
58	Exercise and hypertension. Coronary Artery Disease, 2000, 11, 99-102.	0.3	59
59	Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study. Journal of Hypertension, 2009, 27, 744-752.	0.3	53
60	ADMA, C-Reactive Protein, and Albuminuria in Untreated Essential Hypertension: A Cross-sectional Study. American Journal of Kidney Diseases, 2010, 55, 1050-1059.	2.1	53
61	Time in Therapeutic Range, as a Determinant of Allâ€Cause Mortality in Patients With Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	50
62	Renal Denervation and Symplicity HTN-3. Circulation Research, 2014, 115, 211-214.	2.0	49
63	Albuminuria and Cognitive Decline in People with Diabetes and Normal Renal Function. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1907-1914.	2.2	47
64	Renal Nerve Ablation for Resistant Hypertension. Circulation, 2014, 129, 1440-1451.	1.6	47
65	Orthostatic hypotension: From pathophysiology to clinical applications and therapeutic considerations. Journal of Clinical Hypertension, 2019, 21, 546-554.	1.0	47
66	Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy. American Heart Journal, 1985, 110, 595-599.	1.2	45
67	Cardiorespiratory fitness and coronary heart disease risk factor association in women. Journal of the American College of Cardiology, 1995, 26, 358-364.	1.2	45
68	Metabolic syndrome and insulin resistance in the TROPHY sub-study: Contrasting views in patients with high-normal blood pressure. American Journal of Hypertension, 2005, 18, 3-12.	1.0	45
69	Diuretics, hypokalemia, and cardiac arrhythmias: A critical analysis. American Heart Journal, 1986, 111, 1217-1224.	1.2	44
70	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. American Journal of Nephrology, 2016, 43, 271-280.	1.4	43
71	Effect of Intensive Blood Pressure Control on Gait Speed and Mobility Limitation in Adults 75 Years or Older. JAMA Internal Medicine, 2017, 177, 500.	2.6	43
72	Prognostic Significance of Left Ventricular Diastolic Dysfunction in Patients With Left Ventricular Hypertrophy and Systemic Hypertension (the LIFE Study). American Journal of Cardiology, 2010, 106, 999-1005.	0.7	42

#	Article	IF	Citations
73	Attended and Unattended Automated Office Blood Pressure Measurements Have Better Agreement With Ambulatory Monitoring Than Conventional Office Readings. Journal of the American Heart Association, 2018, 7, .	1.6	42
74	Masked Hypertension and Atherogenesis: The Impact of Apelin and Relaxin Plasma Levels. Journal of Clinical Hypertension, 2013, 15, 333-336.	1.0	41
75	Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. Journal of the American Society of Nephrology: JASN, 2019, 30, 1523-1533.	3.0	41
76	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. Journal of Hypertension, 2010, 28, 2299-2308.	0.3	40
77	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Pressure, 2009, 18, 261-267.	0.7	39
78	In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study. Journal of Hypertension, 2010, 28, 1541-1546.	0.3	39
79	Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. International Journal of Cardiology, 2013, 168, 987-992.	0.8	38
80	Effects of aerobic training on exaggerated blood pressure response to exercise in African-Americans with severe systemic hypertension treated with indapamide Â± verapamil Â± enalapril. American Journal of Cardiology, 1997, 79, 1424-1426.	0.7	37
81	Chronic heart failure and exercise. American Heart Journal, 2000, 140, 21-28.	1.2	37
82	Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study. American Heart Journal, 2003, 145, 919-925.	1.2	37
83	Echocardiographic Wall Motion Abnormalities in Hypertensive Patients With Electrocardiographic Left Ventricular Hypertrophy. Hypertension, 2003, 41, 75-82.	1.3	36
84	Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. American Journal of Hypertension, 2012, 25, 444-450.	1.0	36
85	Effect of Intensive Blood Pressure Lowering on Incident Atrial Fibrillation and P-Wave Indices in the ACCORD Blood Pressure Trial. American Journal of Hypertension, 2016, 29, 1276-1282.	1.0	36
86	Exercise Blood Pressure Response and Left Ventricular Hypertrophy. American Journal of Hypertension, 1989, 2, 114-116.	1.0	35
87	Effects of Moderate Intensity Exercise on Serum Lipids in African-American Men With Severe Systemic Hypertension. American Journal of Cardiology, 1998, 81, 732-735.	0.7	35
88	Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1693-1702.	2.2	32
89	Therapeutic adherence in the elderly: Transdermal clonidine compared to oral verapamil for hypertension. American Journal of Medicine, 1991, 91, S22-S28.	0.6	31
90	Hydrochlorothiazide Is Superior to Isradipine for Reduction of Left Ventricular Mass: Results of a Multicenter Trial fn1fn1This study was supported by an unrestricted grant from Sandoz Pharmaceuticals, East Hanover, New Jersey.fn2fn2To discuss this article on-line, visit the ACC Home Page at http://www.acc.org/membersand click on the JACC Forum. Journal of the American College of Cardiology, 1997, 30, 1802-1808.	1.2	31

#	Article	IF	Citations
91	Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-5.	0.5	31
92	Unintentional overestimation of an expected antihypertensive effect in drug and device trials: Mechanisms and solutions. International Journal of Cardiology, 2014, 172, 29-35.	0.8	31
93	Catheter-based renal denervation for resistant hypertension: Twenty-four month results of the EnligHTNâ„¢ I first-in-human study using a multi-electrode ablation system. International Journal of Cardiology, 2015, 201, 345-350.	0.8	31
94	Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. American Heart Journal, 1998, 136, 734-740.	1.2	30
95	Resistant Hypertension: Diagnosis and Management. Journal of Cardiovascular Pharmacology and Therapeutics, 2006, 11, 113-118.	1.0	30
96	Effects of multielectrode renal denervation on elevated sympathetic nerve activity and insulin resistance in metabolic syndrome. Journal of Hypertension, 2017, 35, 1100-1108.	0.3	30
97	Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnea. Journal of Hypertension, 2013, 31, 352-360.	0.3	30
98	Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opinion on Therapeutic Targets, 2009, 13, 413-425.	1.5	29
99	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and metaâ€analysis of randomized, shamâ€controlled, catheterâ€based trials. Journal of Clinical Hypertension, 2020, 22, 572-584.	1.0	29
100	Cardiovascular Risk Assessment and Triptans. Headache, 2004, 44, S31-S39.	1.8	28
101	Diuretics, Hypokalemia, and Cardiac Arrhythmia: A 20â€Year Controversy. Journal of Clinical Hypertension, 2006, 8, 86-92.	1.0	28
102	Î²-blockers in the management of hypertension: focus on nebivolol. Expert Review of Cardiovascular Therapy, 2008, 6, 471-479.	0.6	28
103	Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. Circulation, 2022, 145, 847-863.	1.6	28
104	Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy). American Journal of Cardiology, 2004, 94, 1076-1080.	0.7	27
105	Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk. Hypertension, 2005, 46, 492-499.	1.3	27
106	Heart rate recovery, exercise capacity, and mortality risk in male veterans. European Journal of Preventive Cardiology, 2012, 19, 177-184.	0.8	27
107	Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	26
108	Renal sympathetic denervation in hypertension. Current Opinion in Nephrology and Hypertension, 2011, 20, 647-653.	1.0	26

#	Article	IF	Citations
109	Carotid Baroreceptor Activation for the Treatment of Resistant Hypertension and Heart Failure. Current Hypertension Reports, 2012, 14, 238-246.	1.5	26
110	Systolicâ€“diastolic hypertension versus isolated systolic hypertension and incident heart failure in older adults: Insights from the Cardiovascular Health Study. International Journal of Cardiology, 2017, 235, 11-16.	0.8	26
111	Effect of Intensive Blood Pressure Reduction on Left Ventricular Mass, Structure, Function, and Fibrosis in the SPRINT-HEART. Hypertension, 2019, 74, 276-284.	1.3	26
112	APOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial. Kidney International Reports, 2017, 2, 713-720.	0.4	25
113	Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. American Heart Journal, 2004, 148, 538-544.	1.2	24
114	Physiciansâ€™ Perceptions and Adherence to Guidelines for the Management of Hypertension: A National, Multicentre, Prospective Study. International Journal of Hypertension, 2012, 2012, 1-11.	0.5	24
115	Transient coronary occlusion with mental stress. American Heart Journal, 1996, 132, 1299-1301.	1.2	23
116	How Dangerous Are Diuretics?. Drugs, 1985, 30, 469-474.	4.9	21
117	Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. Journal of Hypertension, 2008, 26, 844-852.	0.3	21
118	Exercise and cardiovascular outcomes in hypertensive patients in relation to structure and function of left ventricular hypertrophy: the LIFE study. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 242-248.	3.1	21
119	Benefits from Treatment and Control of Patients with Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	20
120	Statin Therapy, Fitness, and Mortality Risk in Middle-Aged Hypertensive Male Veterans. American Journal of Hypertension, 2014, 27, 422-430.	1.0	20
121	Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy. Journal of Hypertension, 2015, 33, 346-353.	0.3	20
122	Left Ventricular Wall Stressâ€“Massâ€“Heart Rate Product and Cardiovascular Events in Treated Hypertensive Patients. Hypertension, 2015, 66, 945-953.	1.3	20
123	Paradoxical Reduction in HDL-C With Fenofibrate and Thiazolidinedione Therapy in Type 2 Diabetes: The ACCORD Lipid Trial. Diabetes Care, 2014, 37, 686-693.	4.3	19
124	Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model. Journal of Hypertension, 2016, 34, 1854-1862.	0.3	19
125	Comparison of Nebivolol Monotherapy Versus Nebivolol in Combination With Other Antihypertensive Therapies for the Treatment of Hypertension. American Journal of Cardiology, 2009, 103, 273-278.	0.7	18
126	Early changes in plasma and urinary potassium in diuretic-treated patients with systemic hypertension. American Journal of Cardiology, 1984, 54, 1015-1019.	0.7	17

#	Article	IF	Citations
127	Inhibition of the renin-angiotensin-aldosterone system to prevent ischemic and atherothrombotic events. American Heart Journal, 2009, 157, S24-S30.	1.2	17
128	Combined renin-angiotensin-aldosterone system inhibition in patients with chronic heart failure secondary to left ventricular systolic dysfunction. American Heart Journal, 2009, 157, S17-S23.	1.2	17
129	Relationship of ambulatory arterial stiffness index with blood pressure response to exercise in the early stages of hypertension. Blood Pressure Monitoring, 2010, 15, 132-138.	0.4	17
130	Home, automated office, and conventional office blood pressure as predictors of cardiovascular risk. Journal of the American Society of Hypertension, 2017, 11, 165-170.e2.	2.3	17
131	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. American Journal of Medicine, 2017, 130, 1465.e27-1465.e39.	0.6	17
132	Now That Renal Denervation Works, How Do We Proceed?. Circulation Research, 2019, 124, 693-695.	2.0	17
133	Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy. Current Pharmaceutical Design, 2014, 20, 6339-6349.	0.9	17
134	Factorial Antihypertensive Study of an Extended-Release Metoprolol and Hydrochlorothiazide Combination. American Journal of Hypertension, 2006, 19, 1217-1225.	1.0	16
135	Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study. Journal of Hypertension, 2008, 26, 1472-1476.	0.3	16
136	Effectiveness of Potassium Chloride or Triamterene in Thiazide Hypokalemia. Archives of Internal Medicine, 1985, 145, 1986.	4.3	15
137	Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study). American Journal of Cardiology, 2002, 89, 399-402.	0.7	15
138	From Hypertension to Heart Failure. Journal of Clinical Hypertension, 2004, 6, 14-17.	1.0	15
139	Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study. International Journal of Cardiology, 2015, 180, 237-242.	0.8	15
140	Effects of Intensive Blood Pressure Control in Patients with and without Albuminuria. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1121-1128.	2.2	15
141	Effects of diuretic therapy and exercise-related arrhythmias in systemic hypertension. American Journal of Cardiology, 1989, 64, 1152-1156.	0.7	14
142	Candesartan cilexetil in cardiovascular disease. Expert Review of Cardiovascular Therapy, 2004, 2, 829-835.	0.6	14
143	Angiotensinâ€Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Africanâ€American Patients With Hypertension. Journal of Clinical Hypertension, 2004, 6, 310-314.	1.0	14
144	PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1816-1824.	2.2	14

#	Article	IF	Citations
145	Unobserved automated office BP is similar to other clinic BP measurements: A prospective randomized study. Journal of Clinical Hypertension, 2018, 20, 1411-1416.	1.0	14
146	Electrocardiographic abnormalities suggestive of myocardial ischemia during upper gastrointestinal bleeding. American Journal of Cardiology, 1995, 75, 312-314.	0.7	13
147	Apelin and Relaxin Plasma Levels in Young Healthy Offspring of Patients With Essential Hypertension. Journal of Clinical Hypertension, 2014, 16, 198-201.	1.0	13
148	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. American Journal of Nephrology, 2017, 45, 136-145.	1.4	13
149	From â€˜essentialâ€™ hypertension to intensive blood pressure lowering: the pros and cons of lower target values. European Heart Journal, 2017, 38, 3258-3271.	1.0	13
150	Low-Dose Combination Treatment for Hypertension Versus Single-Drug TreatmentBisoprolol/Hydrochlorothiazide Versus Amlodipine, Enalapril, and Placebo. American Journal of Therapeutics, 1998, 5, 313-322.	0.5	12
151	Metoprolol Succinate Combination in the Treatment of Hypertension. Angiology, 2009, 60, 608-613.	0.8	12
152	Relation of Impaired Coronary Microcirculation to Increased Urine Albumin Excretion in Patients With Systemic Hypertension and No Epicardial Coronary Arterial Narrowing. American Journal of Cardiology, 2012, 109, 1026-1030.	0.7	12
153	Arterial Stiffness and Emerging Biomarkers. Angiology, 2015, 66, 901-903.	0.8	12
154	Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled hypertensives: a 4-year follow-up study. Journal of Human Hypertension, 2018, 32, 487-493.	1.0	12
155	Attended Versus Unattended Automated Office Blood Pressure: A Systematic Review and Meta-analysis. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 293-303.	1.0	12
156	Effect of Hydrochlorothiazide Therapy on Cardiac Arrhythmias in African-American Men With Systemic Hypertension and Moderate to Severe Left Ventricular Hypertrophy. American Journal of Cardiology, 1996, 78, 886-889.	0.7	11
157	Association of Hemoglobin Delivery With Left Ventricular Structure and Function in Hypertensive Patients. Hypertension, 2006, 47, 868-873.	1.3	11
158	Evaluation and Treatment of Resistant or Difficultâ€toâ€Control Hypertension. Journal of Clinical Hypertension, 2008, 10, 837-843.	1.0	11
159	Electrical stimulation of the renal arterial nerves does not unmask the blindness of renal denervation procedure in swine. International Journal of Cardiology, 2014, 176, 1061-1063.	0.8	11
160	Device-Based Therapy for Drug-Resistant Hypertension: An Update. Current Hypertension Reports, 2016, 18, 64.	1.5	11
161	Renal Fibromuscular Dysplasia: A Not So Common Entity of Secondary Hypertension. Journal of Clinical Hypertension, 2016, 18, 240-246.	1.0	11
162	Improvement in Allâ€Cause Mortality With Blood Pressure Control in a Group of US Veterans With Drugâ€Resistant Hypertension. Journal of Clinical Hypertension, 2016, 18, 33-39.	1.0	11

#	Article	IF	Citations
163	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension. Journal of Hypertension, 2017, 35, 1750-1757.	0.3	11
164	Comparative prognostic value of systolic, diastolic, and pulse pressure. American Journal of Cardiology, 2003, 91, 433-435.	0.7	10
165	Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment. American Journal of Hypertension, 2003, 16, 180-186.	1.0	10
166	National Utilization of Antihypertensive Medications From 2000 to 2006 in the Veterans Health Administration: Focus on Thiazide Diuretics. Journal of Clinical Hypertension, 2008, 10, 770-778.	1.0	10
167	Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Current Vascular Pharmacology, 2014, 12, 55-62.	0.8	10
168	Mild to moderate chronic kidney disease and cardiovascular events in patients with type 2 diabetes mellitus . Vascular Health and Risk Management, 2019, Volume 15, 365-373.	1.0	10
169	Morning Surge and Peak Morning Ambulatory Blood Pressure Versus Automated Office Blood Pressure in Predicting Cardiovascular Disease. High Blood Pressure and Cardiovascular Prevention, 2019, 26, 209-215.	1.0	10
170	Effects of diltiazem, metoprolol, enalapril and hydrochlorothiazide on frequency of ventricular premature complexes. American Journal of Cardiology, 1994, 73, 242-246.	0.7	9
171	Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study). Blood Pressure, 2009, 18, 180-186.	0.7	9
172	The role of exercise in the control of hypertension and cardiovascular risk. Current Opinion in Nephrology and Hypertension, 1996, 5, B153.	1.0	8
173	Efficacy of Low-Dose Combination of Bisoprolol/Hydrochlorothiazide Compared With Amlodipine and Enalapril in Men and Women With Essential Hypertension. American Journal of Cardiology, 1998, 81, 1363-1365.	0.7	8
174	Metabolic Side Effects and Cardiovascular Events of Diuretics: Should a Diuretic Remain the First Choice Therapy in Hypertension Treatment? The Case of Yes. Clinical and Experimental Hypertension, 2007, 29, 503-516.	0.5	8
175	Primary Aldosteronism: Novel Insights. Current Hypertension Reviews, 2020, 16, 19-23.	0.5	8
176	Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study). American Journal of Cardiology, 2005, 95, 280-283.	0.7	7
177	Electrocardiographic and Echocardiographic Detection of Myocardial Infarction in Patients with Left-Ventricular HypertrophyThe LIFE Study. American Journal of Hypertension, 2007, 20, 771-776.	1.0	7
178	Change in Pulse Pressure/Stroke Index in Response to Sustained Blood Pressure Reduction and Its Impact on Left Ventricular Mass and Geometry Changes: the Life Study. American Journal of Hypertension, 2008, 21, 701-707.	1.0	7
179	Implantation of a Carotid Baroreceptor Stimulator in Patients with Pacemakers and Hypertension. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 354-356.	0.5	7
180	Impressive Blood Pressure and Heart Rate Response After Percutaneous Renal Denervation in a Woman With Morbid Obesity and Severe Drugâ€Resistant Hypertension. Journal of Clinical Hypertension, 2013, 15, 852-855.	1.0	7

#	Article	IF	Citations
181	Screening for Primary Aldosteronism: Whom and How?. Journal of Clinical Hypertension, 2015, 17, 547-548.	1.0	7
182	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. Current Vascular Pharmacology, 2017, 16, 66-69.	0.8	7
183	The Role of Mineralocorticoid Receptor Antagonists in Heart Failure with Reduced Ejection Fraction. Current Pharmaceutical Design, 2019, 24, 5517-5524.	0.9	7
184	Low-dose Fixed Combination of Bisoprolol/Hydrochlorothiazide as First Line for Hypertension: A Review of the Rationale and Clinical Evidence. Angiology, 2009, 60, 601-607.	0.8	6
185	Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. Expert Opinion on Therapeutic Targets, 2011, 15, 1347-1353.	1.5	6
186	Renal Sympathetic Denervation: Hibernation or Resurrection?. Cardiology, 2016, 135, 87-97.	0.6	6
187	Important practice lessons from the SPRINT study beyond the blood pressure goal: all well known and now confirmed. Journal of the American Society of Hypertension, 2016, 10, 613-617.	2.3	6
188	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 39.	0.4	6
189	Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?. Current Vascular Pharmacology, 2017, 16, 30-43.	0.8	6
190	Hypertension and Atherosclerosis: Pathophysiology, Mechanisms and Benefits of BP Control. , 2016, , 201-216.		6
191	Regression of hypertensive left ventricular hypertrophy by angiotensin receptor blockade versus beta-blockade: the LIFE trial. American Journal of Hypertension, 2002, 15, A15.	1.0	5
192	Aspirin Under Fire: Aspirin Use in the Primary Prevention of Coronary Heart Disease. Pharmacotherapy, 2005, 25, 847-861.	1.2	5
193	Hypertrophic and Hypertensive Hypertrophic Cardiomyopathyâ€"A True Association?. Angiology, 2010, 61, 92-99.	0.8	5
194	Difficult-to-Treat or Resistant Hypertension: Etiology, Pathophysiology, and Innovative Therapies. International Journal of Hypertension, 2011, 2011, 1-4.	0.5	5
195	Renal Denervation for Sleep Apnea and Resistant Hypertension: Alternative or Complementary to Effective Continuous Positive Airway Pressure Treatment?. Hypertension, 2011, 58, e191; author reply e192.	1.3	5
196	Non-interventional management of resistant hypertension. World Journal of Cardiology, 2014, 6, 1080.	0.5	5
197	The Role of Angiogenesis Inhibitors in Hypertension: Following â€œAriadneâ€™s Threadâ€. American Journal of Hypertension, 2018, 31, 961-969.	1.0	5
198	Pharmacological Management of Diabetic Nephropathy. Current Vascular Pharmacology, 2020, 18, 139-147.	0.8	5

#	Article	IF	Citations
199	Losartan in cardiovascular disease. Future Cardiology, 2005, 1, 433-446.	0.5	4
200	Targeting angiotensin II type I receptors to reduce the risk of stroke in patients with hypertension. Expert Opinion on Therapeutic Targets, 2006, 10, 231-237.	1.5	4
201	A case of influenza type a myocarditis that presents with ST elevation MI, cardiogenic shock, acute renal failure, and rhabdomyolysis and with rapid recovery after treatment with oseltamivir and intra-aortic balloon pump support. Cardiovascular Revascularization Medicine, 2018, 19, 37-42.	0.3	4
202	Hypertensive urgencies during the first wave of COVID-19 pandemic in a tertiary hospital setting: A â€œUâ€• shaped alarming curve.. Archives of Medical Science, 2021, , .	0.4	4
203	To the Editor.â€”Reply. Archives of Internal Medicine, 1986, 146, 1026.	4.3	3
204	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Pressure, 2009, 18, 261-267.	0.7	3
205	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. Expert Opinion on Pharmacotherapy, 2009, 10, 955-966.	0.9	3
206	Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled. Journal of Clinical Hypertension, 2014, 16, 399-400.	1.0	3
207	Olmesartan worsening known thrombocytopenia. A rare side effect of antihypertensive drugs. Hellenic Journal of Cardiology, 2017, 58, 96-97.	0.4	3
208	SPYRAL HTN-OFF MED study: Renal denervation in the spiral orbits of current results and future studies. Hellenic Journal of Cardiology, 2017, 58, 320-321.	0.4	3
209	Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?. Angiology, 2018, 69, 5-9.	0.8	3
210	Insomnia and hypertension: A misty landscape. Journal of Clinical Hypertension, 2019, 21, 835-837.	1.0	3
211	Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia. Journal of Hypertension, 2019, 37, 2145-2153.	0.3	3
212	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. American Journal of Cardiology, 2020, 125, 887-893.	0.7	3
213	The ALLHAT Study Revisited: Do Newer Data From This Trial and Others Indicate Changes in Treatment Guidelines?. Journal of Clinical Hypertension, 2007, 9, 372-380.	1.0	2
214	Telmisartan for Prevention of Cardiovascular Events. New England Journal of Medicine, 2009, 360, 302-303.	13.9	2
215	Protective Effects of Angiotensinâ€Converting Enzyme Inhibitors in Highâ€Risk African American Men With Coronary Heart Disease. Journal of Clinical Hypertension, 2009, 11, 621-626.	1.0	2
216	On Target to Dual Block RAS?. Angiology, 2009, 60, 739-749.	0.8	2

#	Article	IF	Citations
217	Baroreflex Activation Therapy and Resistant Hypertension. Journal of the American College of Cardiology, 2012, 59, 541.	1.2	2
218	The clinical value of automated office blood pressure: What is the latest evidence on attended vs unattended automated readings in clinical practice?. Journal of Clinical Hypertension, 2019, 21, 156-158.	1.0	2
219	Prognostic relevance of visitâ€toâ€visit office blood pressure variability in Systolic Blood Pressure Intervention Trial: Same data, different conclusions?. Journal of Clinical Hypertension, 2018, 20, 1644-1645.	1.0	2
220	Renal Sympathetic Denervation in Isolated Systolic Hypertension. Hypertension, 2019, 74, 255-256.	1.3	2
221	Effect of Intensive Versus Standard Blood Pressure Control on Stroke Subtypes. Hypertension, 2021, 77, 1391-1398.	1.3	2
222	Hypertension in Pregnancy: Unanswered Questions. Current Pharmaceutical Design, 2021, 27, 3795-3803.	0.9	2
223	Tolerability profile of tasosartan, a long-acting angiotensin II AT1 receptor blocker, in the treatment of patients with essential hypertension. Current Therapeutic Research, 1997, 58, 930-943.	0.5	1
224	Eulogy for Edward D. Freis, MD*. American Journal of Cardiology, 2005, 96, 311-312.	0.7	1
225	Response to Letter Regarding Article, â€œRole of Diuretics in the Prevention of Heart Failure: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)â€• Circulation, 2007, 115, .	1.6	1
226	Does rapidity of blood pressure lowering affect outcomes in hypertension treatment?. Current Cardiovascular Risk Reports, 2008, 2, 255-261.	0.8	1
227	Should Target Organ Damage Become a Therapeutic Target?. Journal of Clinical Hypertension, 2013, 15, 710-711.	1.0	1
228	Drug therapy for the patient with resistant hypertension. Future Cardiology, 2015, 11, 191-202.	0.5	1
229	Renal Denervation for Drug-Resistant Hypertension: There Is Still Hope. Cardiovascular Revascularization Medicine, 2015, 16, 202-203.	0.3	1
230	Regarding â€œSevere bilateral renal artery stenosis after transluminal radiofrequency ablation of renal sympathetic nerve plexusâ€• Journal of Vascular Surgery, 2015, 62, 539.	0.6	1
231	Serial changes in vessel walls of renal arteries after catheter-based renal artery denervation: insights from volumetric computed tomography analysis. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 259-266.	0.8	1
232	The Reply. American Journal of Medicine, 2018, 131, e317.	0.6	1
233	Determinants of pulse wave velocity index and potential implementations. Journal of Clinical Hypertension, 2019, 21, 1493-1495.	1.0	1
234	Joint ESH Excellence Centersâ€™ National Meeting on Renal Sympathetic Denervation: a Greek Expertsâ€™ Survey. Hellenic Journal of Cardiology, 2021, 62, 355-358.	0.4	1

#	Article	IF	Citations
235	The Impact of Various Blood Pressure Measurements on Cardiovascular Outcomes. Current Vascular Pharmacology, 2020, 19, 313-322.	0.8	1
236	Diuretics, Potassium, and Ventricular Arrhythmias. JAMA - Journal of the American Medical Association, 1992, 268, 52.	3.8	0
237	Regional cardiac compression due to a large anaerobic bacterial empyema. Clinical Cardiology, 1996, 19, 332-334.	0.7	0
238	Left ventricular hypertrophy: not so much determinant of renal outcome?. Journal of Hypertension, 2011, 29, 622.	0.3	0
239	Achieving Renal Denervation: Catheter-Based and Surgical Management for Neural Ablation in the Management of Hypertension. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2012, 7, 314-322.	0.4	0
240	Response to Letter to the Editor: â€œRenal Artery Stenosis May be Responsible for the Gradual Return of High Blood Pressure After Renal Denervationâ€• Journal of Clinical Hypertension, 2014, 16, 314-314.	1.0	0
241	Selecting Optimum Antihypertensive Therapy. , 2016, , 217-247.		0
242	Renal Denervation: A Historical Perspective. Updates in Hypertension and Cardiovascular Protection, 2016, , 201-213.	0.1	0
243	Geometric patterns of left ventricular hypertrophy: Is geometry alone to be blamed?. Hellenic Journal of Cardiology, 2017, 58, 143-145.	0.4	0
244	Reply. Journal of Hypertension, 2017, 35, 200.	0.3	0
245	Renal sympathetic denervation resurrected; or NOT?. Journal of the American Society of Hypertension, 2017, 11, 700-703.	2.3	0
246	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology: Hypertension, 2019, 3, 100022.	2.2	0
247	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease â€“ A Tribute to Edward D. Freis. , 2019, , 75-88.		0
248	Hypertension Management in African Americans: The AASK and Other Landmark Trial Application. , 2019, , 145-154.		0
249	Well and accurately taken office blood pressure measurements, automated or auscultatory, should still remain the standard of care. Hellenic Journal of Cardiology, 2020, 61, 178-179.	0.4	0
250	Response by Latif et al to Letter Regarding Article, "Stent-Only Versus Adjunctive Balloon Angioplasty Approach for Saphenous Vein Graft Percutaneous Coronary Intervention: Insights From DIVA Trial". Circulation: Cardiovascular Interventions, 2020, 13, e009174.	1.4	0
251	Achieving Renal Denervation: Catheter-Based and Surgical Management for Neural Ablation in the Management of Hypertension. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2012, 7, 314-322.	0.4	0
252	Sympathetic Renal Denervation Using the EnligHTN Multi-electrode Ablation System: The St Jude Experience. , 2015, , 69-79.		0

#	Article	IF	Citations
253	Place of Invasive Procedures in Blood Pressure Control. Updates in Hypertension and Cardiovascular Protection, 2018, , 853-865.	0.1	0
254	Polycythemia hypertonica revisited: a metabolic syndrome with high-renin hypertension?. Journal of Human Hypertension, 2022, , .	1.0	0